Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.

Published byCecilia Chapman Modified over 8 years ago

Similar presentations

Presentation on theme: "Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr."— Presentation transcript:

1 Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr PH, William Cushman MD, Henry Black MD, Lara Simpson MS, Barry Davis MD, PhD. For the ALLHAT Collaborative Research Group Sponsored by the National Heart, Lung and Blood Institute (NHLBI) in collaboration with the Department of Veterans Affairs U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute ALLHAT www.allhat.org

2 Background ALLHAT * In the 90’s several mainly observational studies reported unfavorable cardiovascular outcomes on therapy with DHP-CCB’s in patients with CHD. * Placebo-controlled RCT’s such as HOPE or EUROPA (but not PEACE) concluded that (hypertensive) patients with CHD show benefits from ACE-inhibitor therapy beyond that expected from BP lowering per se. on the other hand:

3 Objective of Present Post-Hoc Analysis ALLHAT Comparison of cardiovascular and other outcomes among 18,102 patients with or without CHD at baseline randomized to the ACE-inhibitor lisinopril or the DHP-CCB amlodipine.

4 42,418 high-risk hypertensive patients 90% previously treated 10% untreated STEP 1 AGENTS Chlorthalidone 12.5-25 mg Amlodipine 2.5-10 mg Lisinopril 10-40 mg Doxazosin 1-8 mg N=15,255 N=9,048 N=9,054 N=9,061 STEP 2 AND 3 AGENTS (5 years) Atenolol 28.0% Clonidine 10.6% Reserpine 4.3% Hydralazine 10.9% Hypertension Trial ALLHAT

5 CHD at Baseline ALLHAT “known prior MI, angina, primary cardiac arrest, coronary artery stenosis >50%, reversible perfusion defect, or major coronary revascularization procedure”

6 Baseline Characteristics by CHD at Baseline CHD at BaselineNo CHD at Baseline Aml (n=2202) Lis (n=2270) Aml (n=6777) Lis (n=6715) SBP/DBP, mean145/83146/83147/84 Age in yrs, mean67.968.166.666.4 On antihypertensive meds (%) 939290 Type 2 diabetes (%) 26274038 Cigarette smoker (%) 15 24 Female (%)36345150 Blacks (%)24 39 On aspirin (%)60592928 ALLHAT

7 1.9 2.0 1.9 1.7 Y3 1.8 1.6 Y2Y4Y1BL Mean # of Meds: 1.7 1.6 1.5 1.7 1.5 1.3 AmlodipineCHD at BL No CHD at BL LisinoprilCHD at BL No CHD at BL mmHg BP Δ =1.1 Δ =1.5 Δ =1.0Δ =1.1 132 134 136 138 140 142 144 146 148 Amlodipine - CHD at BL Amlodipine - No CHD at BL Lisinopril - CHD at BL Lisinopril - No CHD at BL mmHg BP Δ =1.5 Δ =0.8 Δ =1.8 Δ =1.2 Baseline and Follow-up BPs by CHD at BL ALLHAT

8 Events – L vs. A Relative Risk and 95% Confidence Intervals Favors Lisinopril Favors Amlodipine 0.5012 PAD1.19 (1.01-1.40) Revascularization1.00 (0.91-1.11) Angina1.09 (1.00-1.19) HF0.87 (0.78-0.96) GI Bleed1.20 (1.06-1.37) Cancer1.01 (0.91-1.12) ESRD0.99 (0.77-1.26) Combined CVD1.06 (1.00-1.12) Stroke1.23 (1.08-1.41) Combined CHD1.04 (0.97-1.12) Death1.05 (0.97-1.13) CHD1.01 (0.91-1.11) ALLHAT p=0.047 p=0.045

9 Cumulative Event Rates for Primary Endpoint by CHD at Baseline and Treatment Group ALLHAT 0.00 0.05 0.10 0.15 0.20 01234567 Years to Primary Endpoint Amlodipine Lisinopril No CHD at BL 0.00 0.05 0.10 0.15 0.20 Cumulative CHD Rate 01234567 Years to Primary Endpoint Amlodipine Lisinopril CHD at BL RR (95%CI)P value L/A1.15 (0.99-1.32)0.06 RR (95%CI)P value L/A0.99 (0.88-1.13)0.92

10 Secondary Endpoints: Lisinopril versus Amlodipine ALLHAT CHD at BLNo CHD at BL RR (95% CI)P valueRR (95% CI)P value Combined CHD1.07 (0.96-1.20)0.241.02 (0.93-1.12)0.64 All-Cause Mortality1.15 (0.99-1.32)0.061.01 (0.92-1.11)0.78 ESRD0.92 (0.54-1.56)0.751.00 (0.76-1.32)0.99

11 Cumulative Event Rates for Stroke by CHD at Baseline and Treatment Group ALLHAT RR (95%CI)P value L/A1.31 (1.01-1.69)0.04 RR (95%CI)P value L/A1.20 (1.02-1.41)0.03 0.00 0.05 0.10 01234567 Years to Stroke Amlodipine Lisinopril No CHD at BL Cumulative Sstroke Rate 0.00 0.05 0.10 01234567 Years to Stroke Amlodipine Lisinopril CHD at BL

12 Cumulative Event Rates for Heart Failure by CHD at Baseline and Treatment Group ALLHAT RR (95%CI)P value L/A0.91 (0.76-1.09)0.31 RR (95%CI)P value L/A0.85 (0.74-0.97)0.02 0.00 0.05 0.10 0.15 0.20 01234567 Years to HF Amlodipine Lisinopril No CHD at BL 0.00 0.05 0.10 0.15 0.20 Cumulative HF Rate 01234567 Years to HF Amlodipine Lisinopril CHD at BL

13 Cumulative Event Rates for Angina by CHD at Baseline and Treatment Group ALLHAT RR (95%CI)P value L/A0.99 (0.87-1.12)0.87 RR (95%CI)P value L/A1.17 (1.03-1.32)0.02 0.00 0.05 0.10 0.15 0.20 0.25 01234567 Years to Angina Amlodipine Lisinopril No CHD at BL 0.00 0.05 0.10 0.15 0.20 0.25 Cumulative ANG Rate 01234567 Years to Angina Amlodipine Lisinopril CHD at BL

14 Cumulative Event Rates for PAD by CHD at Baseline and Treatment Group ALLHAT RR (95%CI)P value L/A0.93 (0.71-1.21)0.58 RR (95%CI)P value L/A1.39 (1.12-1.71)0.002 0.00 0.05 0.10 Cumulative PAD Rate 01234567 Years to PAD Amlodipine Lisinopril CHD at BL 0.00 0.05 0.10 01234567 Years to PAD Amlodipine Lisinopril No CHD at BL

15 Combined CVD ALLHAT RR (95%CI)P value L/A1.03 (0.94-1.13)0.54 RR (95%CI)P value L/A1.08 (0.99-1.15)0.06 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 Cumulative CCVD Rate 01234567 Years to CCVD Amlodipine Lisinopril CHD at BL 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 01234567 Years to CCVD Amlodipine Lisinopril No CHD at BL

16 Summary ALLHAT Lisinoprilvs.Amlodipine CHD at baselineNo CHD at baseline CHD, mortality, ESRD similar Stroke+31%+20% HF Angina PAD -9% -1% -7% -15% +17% (p=0.07 for interaction) +39% (p=0.02 for interaction) Treated SBP levelsimilar+ 1-2 mmHg Combined CVD+3%+8%

17 Conclusion ALLHAT In hypertensive patients with CHD, lisinopril and amlodipine – based treatment provides equivalent BP control and equivalent rates for most outcomes. Patients with and without CHD have similar higher stroke rates and lower HF rates on lisinopril versus amlodipine. This post-hoc analysis provides no evidence for specific benefits by ACE-inhibitor based treatment in patients with CHD.

18 Events for CHD by Race Relative Risk and 95% Confidence Intervals Revascularization Combined CVD Combined CHD Non-Blacks Favors Lisinopril Favors Amlodipine 0.5012 PAD0.98 (0.72-1.33) 1.00 (0.84-1.19) Angina0.99 (0.86-1.14) HF0.90 (0.73-1.11) GI Bleed1.00 (0.77-1.30) Cancer1.03 (0.82-1.31) ESRD 0.65 (0.33-1.29) 1.03 (0.93-1.15) Stroke1.20 (0.89-1.62) 1.07 (0.95-1.22) Death1.15 (0.97-1.36) CHD1.08 (0.90-1.30) Blacks Favors Lisinopril Favors Amlodipine 0.5012 0.76 (0.43-1.35) 1.17 (0.79-1.73) 0.98 (0.73-1.33) 0.95 (0.66-1.35) 1.20 (0.78-1.86) 0.92 (0.61-1.40) 1.72 (0.68-4.38) 1.02 (0.84-1.24) 1.63 (1.01-2.64) 1.06 (0.82-1.37) 1.14 (0.87-1.49) 0.95 (0.68-1.35) ALLHAT

19 Non-Blacks Favors Lisinopril Favors Amlodipine 0.5012 PAD1.35 (1.04-1.77) Revascularization0.95 (0.82-1.12) Angina1.12 (0.96-1.31) HF0.83 (0.69-0.99) GI Bleed1.27 (1.03-1.55) Cancer0.95 (0.81-1.11) ESRD0.97 (0.63-1.49) Combined CVD1.02 (0.93-1.12) Stroke1.00 (0.79-1.25) Combined CHD0.97 (0.86-1.09) Death0.96 (0.85-1.09) CHD0.91 (0.78-1.06) Blacks Favors Lisinopril Favors Amlodipine 0.5012 1.44 (1.03-2.02) 1.08 (0.81-1.45) 1.24 (1.01-1.52) 0.87 (0.71-1.08) 1.30 (1.03-1.64) 1.10 (0.90-1.34) 1.03 (0.71-1.48) 1.16 (1.03-1.30) 1.48 (1.17-1.88) 1.14 (0.97-1.33) 1.08 (0.94-1.25) 1.17 (0.95-1.43) Events for No CHD by Race Relative Risk and 95% Confidence Intervals ALLHAT

20 Events for Non-Blacks by CHD Status Relative Risk and 95% Confidence Intervals

21 ALLHAT Events for Blacks by CHD Status Relative Risk and 95% Confidence Intervals

22 Outcomes L vs. A: RR and 95% Confidence Intervals CHD at Baseline Favors Lisinopril Favors Amlodipine 0.5012 PAD 0.93 (0.71-1.21) Revascularization 1.03 (0.88-1.20) Angina 0.99 (0.87-1.12) HF 0.91 (0.76-1.09) GI Bleed 1.05 (0.84-1.32) Cancer 1.01 (0.82-1.24) ESRD 0.92 (0.54-1.56) Combined CVD 1.03 (0.94-1.13) Stroke 1.31 (1.01-1.69) Combined CHD 1.07 (0.96-1.20) Death 1.15 (0.99-1.32) CHD 1.05 (0.89-1.24) No CHD at Baseline Favors Lisinopril Favors Amlodipine 0.5012 1.39 (1.12-1.71) 0.98 (0.86-1.13) 1.17 (1.03-1.32) 0.85 (0.74-0.97) 1.28 (1.10-1.50) 1.01 (0.89-1.14) 1.00 (0.76-1.32) 1.07 (0.99-1.15) 1.20 (1.02-1.41) 1.02 (0.93-1.12) 1.01 (0.92-1.11) 0.99 (0.88-1.13) ALLHAT

23 Outcomes A vs. C: RR and 95% Confidence Intervals No CHD at Baseline Favors Amlodipine Favors Chlorthalidone 0.5012 0.79 (0.66-0.96) 1.08 (0.96-1.23) 0.99 (0.88-1.11) 1.48 (1.30-1.68) 0.88 (0.76-1.02) 1.06 (0.95-1.18) 1.23 (0.95-1.60) 1.05 (0.98-1.12) 0.96 (0.82-1.11) 1.02 (0.93-1.11) 0.99 (0.91-1.08) 1.01 (0.90-1.13) CHD at Baseline Favors Amlodipine Favors Chlorthalidone 0.5012 PAD 1.04 (0.82-1.31) Revascularization 1.16 (1.00-1.33) Angina 1.10 (0.98-1.24) HF 1.29 (1.09-1.52) GI Bleed 1.00 (0.82-1.23) Cancer 0.92 (0.77-1.10) ESRD 0.88 (0.56-1.38) Combined CVD 1.07 (0.98-1.16) Stroke 0.90 (0.71-1.13) Combined CHD 1.02 (0.92-1.13) Death 0.89 (0.79-1.01) CHD 0.95 (0.82-1.10) ALLHAT

24 Outcomes A vs. C in Blacks: RR and 95% Confidence Intervals CHD at Baseline in Blacks Favors Amlodipine Favors Chlorthalidone 0.5012 PAD 1.18 (0.73-1.91) Revascularization 1.37 (0.94-1.99) Angina 1.08 (0.83-1.41) HF 1.47 (1.06-2.04) GI Bleed 0.94 (0.63-1.39) Cancer 1.07 (0.75-1.55) ESRD 0.70 (0.29-1.68) Combined CVD 1.16 (0.97-1.38) Stroke 0.89 (0.56-1.42) Combined CHD 1.19 (0.94-1.50) Death 0.96 (0.76-1.23) CHD 1.19 (0.87-1.61) No CHD at Baseline in Blacks Favors Amlodipine Favors Chlorthalidone 0.5012 0.77 (0.56-1.05) 0.97 (0.75-1.27) 1.10 (0.91-1.35) 1.53 (1.26-1.88) 1.01 (0.81-1.26) 0.95 (0.79-1.14) 1.27 (0.90-1.80) 1.05 (0.94-1.16) 0.96 (0.76-1.21) 1.00 (0.87-1.16) 0.99 (0.87-1.13) 0.95 (0.79-1.15) ALLHAT

25 Outcomes A vs. C in Non-Blacks: RR and 95% Confidence Intervals CHD at Baseline in Non-Blacks Favors Amlodipine Favors Chlorthalidone 0.5012 PAD1.00 (0.76-1.31) Revascularization1.12 (0.96-1.30) Angina1.11 (0.97-1.26) HF1.24 (1.03-1.49) GI Bleed1.03 (0.81-1.30) Cancer0.87 (0.71-1.08) ESRD1.96 (0.56-1.62) Combined CVD1.04 (0.95-1.14) Stroke0.90(0.69-1.18) Combined CHD0.98 (0.87-1.10) Death0.87 (0.75-1.01) CHD0.89 (0.76-1.05) No CHD at Baseline in Non-Blacks Favors Amlodipine Favors Chlorthalidone 0.5012 0.81 (0.64-1.04) 1.12 (0.97-1.29) 0.94 (0.82-1.08) 1.44 (1.23-1.70) 0.80 (0.67-0.97) 1.13 (0.98-1.30) 1.18 (0.79-1.74) 1.05 (0.97-1.14) 0.95 (0.78-1.16) 1.02 (0.92-1.17) 0.99 (0.89-1.11) 1.04 (0.91-1.10) ALLHAT

26 Outcomes L vs. C: RR and 95% Confidence Intervals No CHD at Baseline Favors Lisinopril Favors Chlorthalidone 0.5012 1.10 (0.92-1.31) 1.06 (0.94-1.21) 1.16 (1.04-1.29) 1.25 (1.09-1.43) 1.13 (1.00-1.29) 1.06 (0.95-1.19) 1.23 (0.95-1.60) 1.12 (1.05-1.20) 1.15 (1.00-1.32) 1.04 (0.96-1.13) 1.01 (0.93-1.09) 1.00 (0.90-1.12) CHD at Baseline Favors Lisinopril Favors Chlorthalidone 0.5012 PAD 0.96 (0.76-1.22) Revascularization 1.18 (1.03-1.36) Angina 1.09 (0.97-1.22) HF 1.18 (1.00-1.39) GI Bleed 1.06 (0.87-1.29) Cancer 0.93 (0.77-1.11) ESRD 0.80 (0.51-1.28) Combined CVD 1.10 (1.01-1.19) Stroke 1.17 (0.95-1.45) Combined CHD 1.09 (0.99-1.21) Death 1.02 (0.91-1.15) CHD 1.00 (0.87-1.15) ALLHAT

27 Outcomes L vs. C in Blacks: RR and 95% Confidence Intervals CHD at Baseline in Blacks Favors Lisinopril Favors Chlorthalidone 0.5012 PAD 0.90 (0.54-1.53) Revascularization 1.59(1.11-2.28) Angina 1.06 (0.81-1.38) HF 1.39 (0.99-1.94) GI Bleed 1.13 (0.78-1.64 Cancer 1.00 (0.69-1.45) ESRD 1.21 (0.58-2.52) Combined CVD 1.18 (0.99-1.40) Stroke 1.45 (0.98-2.16) Combined CHD 1.26 (1.01-1.59) Death 1.10 (0.88-1.39) CHD 1.14 (0.83-1.55) No CHD at Baseline in Blacks Favors Lisinopril Favors Chlorthalidone 0.5012 1.11 (0.84-1.47) 1.05 (0.81-1.36) 1.37 (1.14-1.65) 1.34 (1.09-1.65) 1.32 (1.07-1.62) 1.04 (0.88-1.24) 1.30 (0.92-1.83) 1.22 (1.10-1.35) 1.43 (1.16-1.76) 1.14 (0.99-1.32) 1.07 (0.95-1.22) 1.11 (0.93-1.33) ALLHAT

28 Outcomes L vs. C in Non-Blacks: RR and 95% Confidence Intervals No CHD at Baseline in Non-Blacks Favors Lisinopril Favors Chlorthalidone 0.5012 1.10 (0.88-1.37) 1.07 (0.93-1.24) 1.06 (0.92-1.21) 1.19 (1.00-1.42) 1.02 (0.85-1.21) 1.08 (0.93-1.24) 1.15 (0.77-1.71) 1.07 (0.99-1.16) 0.95 (0.77-1.16) 0.99 (0.89-1.10) 0.96 (0.86-1.07) 0.94 (0.82-1.09) CHD at Baseline in Non-Blacks Favors Lisinopril Favors Chlorthalidone 0.5012 PAD0.98 (0.75-1.28) Revascularization1.12 (0.96-1.30) Angina1.10 (0.96-1.24) HF1.12 (0.92-1.35) GI Bleed1.03 (0.82-1.30) Cancer0.91 (0.74-1.11) ESRD 0.63 (0.34-1.16) Combined CVD1.08 (0.98-1.18) Stroke1.08 (0.83-1.39) Combined CHD1.05 (0.94-1.17) Death1.00 (0.86-1.15) CHD0.97(0.83-1.13) ALLHAT

Download ppt "Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr."

Similar presentations

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.
Www.allhatresearch.org ALLHAT New Research Opportunities.

ALLHAT New Research Opportunities.
11/2/2005 1 Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Valsartan Antihypertensive Long-Term Use Evaluation Results

Valsartan Antihypertensive Long-Term Use Evaluation Results
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.

Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:2998-3007 ALLHAT- LLT.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
6 / 5 / 2006 - 1 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Similar presentations

Ads by Google